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In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more
than 7,000 rare diseases today but relatively few specific therapies for them, mainly because the manufacturers cannot recoup their drug development costs.
Orphan drug status allows sponsors to apply for incentives such as the Orphan Drug Tax
Credit (ODTC), marketing exclusivity for seven years for the first orphan drug for a given
rare disease, and an attractive drug-pricing scheme, amongst other benefits.
Orphan drug trials are generally single arm (no placebo arm), nonrandomized, and open
label. Safety Phase 1 trials are not usually required, and Phases 2 and 3 can be combined
when the patient population is very low.
Sponsors of an orphan drug can make use of expedited Food and Drug Administration
(FDA) programs such as the Fast Track, Breakthrough Therapy, and Priority Review designations, as well as the Accelerated Approval pathway and unique grant funding
opportunities, such as the Orphan Products Clinical Trials Grant program.
The FDA facilitates patient-focused drug development (PFDD) meetings, wherein they
collect patient experience data from the patients, their family members, their caregivers,
and disease foundations. These data can help the orphan drug developers for a given rare
disease in determining clinical endpoints and the route of therapy administration for their
clinical trials.

Introduction
During the 1990s, the pharmaceutical industry flourished due to the discoveries and introduction
of small molecule “blockbuster” drugs, or drugs that bring pharmaceutical companies high annual
1
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sales, into the market. When these drugs went off-patent in the 2000s, there was a rise in the
generics industry. Since pharmaceutical companies struggle to come up with new drugs, and their
previous discoveries are available as cheaper generics, many companies have started developing
drugs for rare diseases, known as orphan drugs. These so-called “niche busters” constitute the
fastest-growing area of drug development, with 14 orphan drugs approved between October and
December 2017 (Pariser; Sharma et al.; Office of the Commissioner, “FDA-TRACK: AgencyWide Program Performance”).
Orphan drugs are medicines or vaccines intended to treat, prevent, or diagnose a rare disease. In
the United States, the FDA defines a rare disease as a disease or a condition that affects fewer than
200,000 patients in the country. More than 7,000 rare diseases are estimated to exist today, affecting approximately 6% to 8% of the world population (Melnikova; Mwamburi et al.).
There is a scarcity of treatments for rare diseases, with fewer than one in ten rare disease patients
receiving disease-specific treatment. Drug development for rare diseases is often limited by the
large cost of investing in an original pharmaceutical agent with poor profit potential, given the
small patient size per rare disease indication. Other obstacles include limited understanding of the
disease, difficulty in identifying patients for trial recruitment, and trouble in identifying clinical
centres with expertise in the disease to run the trials (Melnikova).
Nonetheless, 39% of the novel drugs approved by the FDA Center for Drug Evaluation and
Research (CDER) in 2017 were orphan drugs, mainly due to the provisions of the Orphan Drug
Act of 1983 (“2017 New Drug Therapy Approvals”). An increase in this trend is expected in the
future. It is therefore important to understand the critical regulations and the policy initiatives for
orphan drugs that exist in our country, which are explained in this chapter.

IND Process
The first formal step for a sponsor who is ready to initiate clinical studies for a promising drug is
to file for an Investigational New Drug (IND) application. A pre-IND meeting with the FDA is
strongly advised. The IND application includes available information about the drug—data from
preclinical, animal, and other studies indicating that it is reasonable to begin human trials (Center
for Drug Evaluation and Research, “Investigational New Drug (IND) Application”) (see the chapter on “FDA Drug Regulation: Investigational New Drug Applications”).
Early communication with the FDA is essential for the progress of a drug’s approval process. The
CDER reviews most orphan drug applications, and the Office of Orphan Products Development
(OOPD) promotes orphan drug development and provides grants for the same. It is advised to
contact these organizations regularly (Institute of Medicine (US) Committee on Accelerating Rare
Diseases Research and Orphan Product Development; West).
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The ideal time to begin communicating with the FDA is prior to filing an IND application (Pariser).
Timely review of IND submissions by the FDA, along with their feedback to sponsors, can result
in greater efficiency of the drug development process. At the sponsor’s request, the FDA will, if
possible, provide advice on specific IND matters (Center for Drug Evaluation and Research, “Best
Practices for Communication Between IND Sponsors and FDA During Drug Development”).
The officials whom the sponsors should contact are usually the regulatory project managers
(RPMs) in the CDER review divisions or the Center for Biologics Evaluation and Research
(CBER) review offices (collectively called “review division RPMs”). The review division RPMs
and specific functional area RPMs are referred to as “FDA RPMs.”
FDA RPMs communicate via written correspondence, email, fax, or telephone. They are the primary contacts for facilitating the timely resolution of technical, scientific, and regulatory
questions, conflicts, or communication challenges between sponsors and the review teams. It is
advised to communicate via a telephone call for any time-sensitive issue and later to follow up
with a written communication (e.g., email, submission, or letter), so that there is a documentation
of the decisions, agreements, or action terms that arose during the interaction (Center for Drug
Evaluation and Research, “Best Practices for Communication Between IND Sponsors and FDA
During Drug Development”). The FDA website lists the contact representatives and telephone
numbers of different departments involved in different stages of the orphan drug development
process. The Office of New Drugs (OND) and the CDER together provide guidance under the
Rare Diseases Program. If the sponsor is unsure about whom to call or is not quite ready for clinical
trials but has some questions, they can contact either the associate director for rare diseases or the
regulatory scientist (Center for Drug Evaluation and Research, “Rare Diseases Program”).
Formal meetings at critical points in the drug development process are useful for resolving questions and issues regarding drug development plans, the evidence required to demonstrate the
effectiveness of the orphan drug, drug safety, clinical trial design, and product quality. These
meetings help to minimize wasteful expenditures of time and resources, speeding up the drug
development and evaluation process (Center for Drug Evaluation and Research, “Best Practices
for Communication Between IND Sponsors and FDA During Drug Development”).

Orphan Drug Designation
The Orphan Drug Act (ODA) grants a special status to a drug or a biologic product that is intended
to treat a rare condition or disease, upon the request of the sponsor. This status is referred to as
“orphan designation” or “orphan status” (Office of the Commissioner, “Designating an Orphan
Drug or Biologic”).
Before the sponsor can apply for drug approval under the Orphan Drug Act and before the sponsors
are eligible for incentives like the Orphan Products Grant, they must apply and receive the orphan
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designation from the FDA (Institute of Medicine (US) Committee on Accelerating Rare Diseases
Research and Orphan Product Development).
The sponsor can submit the application for the designation anytime in the drug development process before the submission of a marketing application for the drug of the same rare disease
(“Electronic Code of Federal Regulations”). However, it is recommended that the application be
done before the IND studies as it helps to design the trials when the requirements regarding clinical
endpoints are known beforehand.
The request for designation must be submitted to the OOPD with the information required in CFR
316.20 and 316.21 (Office of the Commissioner, “Designating an Orphan Drug or Biologic”).
Formal, preclinical study data are not required, since the FDA wants evidence of efficacy and the
“scientific rationale” for the use of the drug. The applicant does not need to have animal toxicology
data; only the results of efficacy studies conducted in an animal model for the human disease are
needed (“Electronic Code of Federal Regulations”). The applicant may provide clinical data, animal studies, or in vitro data, but if sufficient information exists in published literature, that may
suffice (Antos).
The sponsor must submit documentation of the estimated prevalence of the disease or condition
for which the drug is being developed, together with a list of the sources for the estimate, in order
to prove that the drug would be administered in the U.S. to fewer than 200,000 patients. “Prevalence” is the number of persons in the U.S. who have been diagnosed with the disease at the time
of the submission of the request for designation. If the drug is to treat a disease that affects a larger
number of people, it may still be designated as an orphan if it is expected that the costs of research
and development of the drug for a particular medical indication cannot be recovered by sales in
the U.S. This is rare, and the sponsors must submit supporting data related to the cost of their
development activities (“Electronic Code of Federal Regulations”).
More than one sponsor may receive orphan drug designation of the same drug for the same rare
disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation (“Electronic Code of Federal Regulations”). However, only the sponsor who
receives the first FDA approval can receive orphan drug marketing exclusivity (discussed later).
A manufacturer may obtain multiple orphan designations and approvals for different indications
for the same product (Institute of Medicine (US) Committee on Accelerating Rare Diseases
Research and Orphan Product Development).

Regulation of Biologics
Biologics are an important part of the orphan drug development, as certain rare diseases require
therapies based on biologics, such as monoclonal antibodies, vaccines, and blood-based clotting
factors, among others. Hence, it is important to understand the regulation of biologics by the FDA

https://repository.upenn.edu/ace/vol1/iss3/13

4

ORPHAN DRUGS

(see the chapter on “Intellectual Property Protection for Biologics”). Generally, biologic drugs are
held to the same standard of efficacy and safety as nonbiologic drugs.
In 2003, the FDA transferred responsibility for review and approval of most therapeutic biologics
from CBER to CDER. Nonetheless, the CBER continues to oversee vaccines, antitoxins, antivenins, venoms, allergenic products, blood, and blood products. Depending on the category of the
product being developed, the sponsor can approach the corresponding organization (Institute of
Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development).
Although the U.S. was the first country to introduce orphan drug legislation in 1983, Japan,
Australia, and the EU followed suit soon after. However there are certain differences in how
orphan drugs are handled in each of them. Sponsors are required to file for an orphan drug
designation in all of these countries (Table 1). While there is no national plan for orphan drugs and
rare diseases in the U.S., Japan, and Australia, there is one in place in the EU. All these countries
allow independent marketing authorization, with Japan and the EU providing up to ten years of
marketing exclusivity as opposed to seven years in the U.S. Australia does not allow marketing
exclusivity to the manufacturers. In terms of pricing, Australia and Japan have a fixed pricing
model, whereas different countries in the EU have different policies ranging from fixed pricing to
free pricing and also reference-based pricing (Gammie et al.).

New Drug Application/Biologics License Application
Approval of all drugs must be based on substantial evidence of efficacy in preventing or treating
the specific condition, along with evidence of safety for that use. The FDA expects sponsors to
have an in-depth understanding of the disease and its natural history, which is not usually available
for rare conditions. The FDA does not require that natural history studies be conducted, but when
knowledge about the disease is insufficient to guide clinical development, a well-designed natural
history study may help in designing an efficient drug development program (Center for Drug Evaluation and Research, “Rare Diseases: Common Issues in Drug Development Guidance for
Industry”).
A New Drug Application (NDA) or a Biologics License Application (BLA) is submitted for
approval of the drug to be launched in the market, and it contains the results from the human
clinical trials. An NDA is for the market approval of small molecule drugs, whereas a BLA is for
the approval of biologics. The required substantial evidence of efficacy and safety is based on the
results of two or more (for common diseases) and sometimes only one (for rare diseases) adequate
and well-controlled (A&WC) investigations designed and conducted such that they are able to
“distinguish the effect of a drug from other influences, such as spontaneous change in the course
of a disease, placebo effect, or biased observation” (21 CFR 314.126, 2018).
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Table 1. Orphan Drug Benefits in Some Other Major Countries
(Adapted from (Gammie et al.)).
Country

Orphan Drug
Designation

Marketing
Exclusivity

Financial
Incentives

Nonfinancial
Incentives

Pricing

Australia

Yes

No

Fee reduction
for marketing
authorization
approval

Pre-licensing
access,
regulatory
assistance

Fixed

Canada

No

No

Tax incentives,
fee reduction
for marketing
authorization

Pre-licensing
access,
scientific
advice,
protocol
assistance,
regulatory
assistance

Reference
pricing

Japan

Yes

10 years

Financial
subsidies, tax
credits, user
fee waivers

Priority
review, fast
track approval,
free protocol
assistance

Fixed = cost +
10%

EU5
(France,
Germany,
Italy, Spain,
U.K.)

Yes

10 years

Reduced
rebates in
Spain and tax
exemptions in
France

Pre-licensing
access in all
EU5 countries,
protocol
assistance and
scientific
advice in
France and
Italy

Free pricing
in Germany,
reference
pricing in
Italy, fixed
pricing in
Spain and the
U.K, and
price
negotiations
in France

Rare disease interventional trials differ from those in non-rare conditions, with notable differences
in enrollment, design, blinding, and randomization. For clinical trials of rare diseases, there is
frequently no requirement for a placebo arm and a safety Phase 1 study in healthy volunteers. For
diseases with a very small population, the FDA accepts trials where Phase 2 and Phase 3 are condensed together to test for efficacy as well as safety in the patients. A study done in 2014 shows
that the majority of the rare disease clinical trials between 2006 and 2012 enrolled fewer
participants, were more likely to be single arm, nonrandomized, and open label when compared to
the non-rare disease clinical trials (Bell and Tudur Smith).
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Orphan Products Clinical Trials Grants Program and
Other Resources
Originally called the Orphan Products Grants, these grants are provided by the FDA for clinical
studies on safety and/or effectiveness that will either result in or substantially contribute to market
approval of these products for rare diseases. These grants are funded by the FDA’s Office of
Orphan Products Development (OOPD). The application for these grants must include a clear documentation of the estimated prevalence of the orphan disease/condition—showing that it is
intended to treat a disease with fewer than 200,000 patients in the U.S.—and an explanation of
how the proposed clinical study will provide the essential data needed for product development. It
is not necessary for a drug or biologic product to hold orphan drug designation to be eligible for
the grant program.
The OOPD receives about 100 applications per year and has funded over 700 studies so far. In
general, the OOPD grant funding lasts between three and four years. Phase 1 studies are eligible
for up to $250,000 per year for up to three years. Phase 2 and 3 studies are eligible for up to
$500,000 per year for up to four years (Office of the Commissioner, “Orphan Products Clinical
Trials Grants Program”).
The National Organization for Rare Disorders’ (NORD) Research Grant Program provides seed
grants to academic scientists in the U.S. or outside, for translational or clinical studies related to
the development of potential new diagnostics or treatments for rare diseases. Out of each grant
awarded between $30,000 and $50,000, NORD uses $5,000 to cover the administrative expenses
and direct costs of initiating a request for proposals (RFP). A search for researchers who have
published journal articles about a specific disease in the last two to five years is conducted in order
to reach the most expert scientists. Each research proposal is reviewed by NORD’s Medical Advisory Committee, which recommends funding for the highest-scored proposals. After the grant is
awarded, NORD monitors the progress of the research, processing biannual reports to NORD’s
Medical Advisory Committee (“Research Grant Program”).
The NIH’s National Center for Advancing Translational Sciences (NCATS) collaborates with the
National Human Genome Research Institute (NHGRI) to support the Genetic and Rare Diseases
Information Center (GARD). GARD was established to help the researchers working in this space
by providing fundamental information and resources to formalize their study protocols. GARD
information specialists can provide custom literature searches, GARD’s rare disease list, and a
contact network of advocacy organization. These organizations may collaborate in the research
and assist the sponsors in the recruitment of a team. They can also direct the researchers to NIH
programs that support rare disease research, such as the Rare Diseases Clinical Research Network
(RDCRN), Therapeutics for Rare and Neglected Diseases (TRND), and the Bridging Interventional Development Gaps program (BrIDGs) (NCATS NIH). These programs are funded by the
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NCATS to assist researchers with developing clinical trials or therapeutic agents. There are
foundations for specific diseases listed on the GARD website that provide funding resources to
researchers working on that particular condition. For example, the Prader-Willi Syndrome
Association (PWSA) offers one- to two-year grants for a maximum of $100,000 for projects aimed
at discovering and developing treatments, cures, and technologies benefiting those with PraderWilli syndrome (Genetic and Rare Diseases Information Center (GARD) and National Center for
Advancing Transnational Sciences).

Key Financial Incentives of Orphan Drug Designation
Figure 1. Financial Incentives of Orphan Drug Designation.

Orphan drug tax credit (ODTC)
The developers of an orphan drug get a tax credit for 50% of qualified clinical trials cost plus seven
years of market exclusivity. Since the credit’s inception in 1983, the FDA has approved more than
500 such drugs, as opposed to only 10 prior to it. However, congressional Republicans proposed
to repeal the orphan drug tax credit as part of a U.S. tax reform package (Cunningham), and the
senate bill proposed to decrease it to 27.5% (Dickey). The tax credit has been a huge financial
incentive for the orphan drug manufacturers, and the credit’s uncertain future spurred a large-scale
“Save Orphan Drugs” movement against the repealment of the tax credit. The National Organization for Rare Disorders (NORD) strongly advocated that the ODTC be strengthened, or at the very
least maintained at 27.5% and not reduced any further(Jensen). However, as of this writing, the
ODTC has been reduced to 25% (Wechsler).

Prescription Drug User Fee Act (PDUFA) exemption
The FDA has the authority to assess and collect user fees for certain drug and biologics license
applications. Pharmaceutical companies pay fees for certain new human drug applications, biologics applications, and supplements submitted to the agency for review. This fee is around $2.2
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million in value (Antos). Review of an application by the FDA cannot begin until the fee has been
submitted.
A human drug NDA/BLA application for an orphan drug is not subject to an application fee unless
the human drug application includes an indication other than the rare condition. Form FDA 3397,
the PDUFA user fee cover sheet, is designed to provide the minimum necessary information to
determine whether a fee is required for review of an application (Center for Drug Evaluation and
Research, “PDUFA User Fee Cover Sheet”). If an application qualifies for an orphan exemption,
the applicant does not need to send the FDA a written request. The applicant should simply notify
the FDA that they are claiming the orphan exemption when they complete and submit FDA Form
3397. This form should be included with the application or supplement, and a brief statement
claiming the orphan exception should be included in the cover letter (Center for Drug Evaluation
and Research, “User Fee Waivers, Reductions, and Refunds for Drug and Biological Products”).

Marketing exclusivity and free pricing
Marketing exclusivity is given to orphan drug developers in order to provide several years to
recover their drug development costs. The FDA’s orphan drug exclusivity (ODE) period runs for
seven years from the time of approval of the NDA or BLA. During the marketing exclusivity
period, the FDA cannot approve a generic drug abbreviated new drug application (ANDA) for the
same drug or brand name drug (full NDA or BLA application) for the same rare disease indication
(Seoane-Vazquez et al.; Lal). However, the same drug can receive approval for a different disease
indication, and no limits are currently put in place on the number of drugs that may be selected for
the same rare disease profile.
Pricing of the orphan drugs is unique in that it is designed to retrieve the costs of R&D from a
small number of patients, compared to the pricing model of other drugs, where pricing is often
based on the capacity of the customer to pay. Given this, the marketing exclusivity, and the lack
of therapeutic alternatives, orphan drugs are relatively expensive. Spark Therapeutics’ Luxturna
costs $850,000 for a one-time gene therapy treatment for a rare, inherited retinal disease that can
lead to blindness (Tirrell). One of the reasons for this is that patients with rare diseases often have
a high willingness to pay, given the limited therapeutic alternatives and the life-threatening or
chronically debilitating nature of many rare diseases. Pricing is also influenced by the change in
quality of life in a more cost-effective approach. In other words, a drug that could provide a cure
will be priced higher than a drug that provides just symptomatic relief or treatment. Therefore,
third-party payers (insurance companies) are generally forced to pay the manufacturer’s high price.
In addition, the free pricing scheme in the U.S. allows the manufacturer to set the price at their
discretion. In comparison, in different European countries, pricing is controlled by a single-payer
system and cost referencing with other nations (Gammie et al.).
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Eligibility for Expedited Approval Processes
Figure 2. Four Successful Rapid Approval Processes Allocated by the FDA.

Out of the CDER new molecular entity (NME) approvals between 2008 and 2016, a significantly
higher number of orphan drugs used expedited clinical development programs compared to the
non-rare disease drugs (Moscicki). If the drug is eligible, the sponsor can make use of any of the
four rapid-approval processes allocated by the FDA (Figure 2):

Fast Track (designation)
This designation facilitates the development and speeds up the FDA review process of drugs that
would treat serious conditions and fill an unmet medical need. To be eligible as a drug that treats
a serious condition, the drug must positively impact such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition
to a more serious one. Filling an unmet need means that no current therapy is available for the
condition or that the proposed therapy is potentially better than available therapies (see the chapter
“Identifying Unmet Needs: Problems that Need Solutions”). If there are available therapies, a Fast
Track drug must show some advantage over available therapy, such as evidence of superior
effectiveness, improved effectiveness on serious outcomes, or lesser side effects (Office of the
Commissioner, “Fast Track”).
The sponsor can initiate the request for Fast Track designation anytime during the drug
development process. The FDA will review and make a decision within 60 days from the request.
The type of data required are usually preliminary nonclinical and mechanistic or clinical data
(Krulewitz). Ideally, the sponsor should submit the application no later than the pre-BLA or the

https://repository.upenn.edu/ace/vol1/iss3/13

10

ORPHAN DRUGS

pre-NDA meeting (Center for Drug Evaluation and Research, “Expedited Programs for Serious
Conditions––Drugs and Biologics”).
The benefits of Fast Track designation include more frequent meetings and written communication
with the FDA, and rolling review. Rolling review refers to the ability of the FDA to begin review
of the BLA or NDA as sections are completed, rather than waiting for the finalized NDA or BLA
to begin the review (Office of the Commissioner, “Fast Track”).

Breakthrough Therapy (designation)
This program is similar to the Fast Track program in providing quick review of drugs that are
intended to treat a serious condition and are better than any available therapy. The most important
difference between the two is the type of data that needs to be submitted to get a Breakthrough
Therapy designation, which is preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over available therapy on (a) clinically significant endpoint(s).
Substantial improvement is judged on the basis of the magnitude of the treatment effects and the
importance of the observed clinical outcome. A clinically significant endpoint is one that measures
an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious
consequences of the disease. It can also refer to findings that suggest an effect on IMM or serious
symptoms (Office of the Commissioner, “Breakthrough Therapy”).
Ideally, a Breakthrough Therapy designation request should be received by the FDA from the
sponsor no later than the end-of-Phase-2 meetings. The FDA responds to the request within 60
days of the receipt of request (Office of the Commissioner, “Breakthrough Therapy”).
Along with the benefits of a Fast Track designation, Breakthrough Therapy drug sponsors are also
given intensive guidance on an efficient drug development program and have the involvement of
FDA senior managers. It is fairly common for a drug on the fast track to be granted Breakthrough
Therapy designation during the drug development process (Krulewitz; Office of the Commissioner, “Breakthrough Therapy”).

Accelerated Approval (approval pathway)
Instituted in 1992 by the FDA, Accelerated Approval regulations allow drugs for serious
conditions that fill an unmet medical need to be approved based on a surrogate endpoint. This
endpoint should be a marker like a laboratory measure or a radiographic image, but is not itself a
clinical benefit. Studies demonstrating this must be A&WC (Office of the Commissioner, “Accelerated Approval”).
The sponsor should discuss the possibility of accelerated approval with the review division during
development, supporting, for example, the use of the planned endpoint as a basis for approval and
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discussing the confirmatory trials, which should usually be already underway at the time of approval (Center for Drug Evaluation and Research, “Expedited Programs for Serious Conditions––
Drugs and Biologics”).
It is important to note here that the sponsor is required to conduct additional clinical trials after the
approval (Phase 4 or post-market surveillance) of the drug to confirm the clinical benefit. Until the
clinical benefit is confirmed, the label mentions that the use of the drug has not shown clinical
benefit yet. Moreover, failure to do these Phase 4 clinical trials can result in removal of the drug
from the market (Krulewitz).

Priority Review (designation)
In 1992, under the PDUFA, the FDA agreed to a Priority Review designation of any drug for which
the agency would take action within six months to review the application, as opposed to ten months
otherwise. The sponsor must submit an application (original or efficacy supplement) for a drug
that treats a serious condition and, if approved, would provide a significant improvement in safety
or effectiveness. Other eligibility criteria can be seen on the FDA website (Office of the Commissioner, “Priority Review”).
The sponsor must submit the request for the original BLA or NDA, or the efficacy supplement.
The FDA responds within 60 days after the submission of request (Center for Drug Evaluation and
Research, “Expedited Programs for Serious Conditions––Drugs and Biologics”).

Seeking Expert Guidance
Partnering with clinical and/or regulatory experts who have relevant experience could help guide
the developers of an orphan drug to approval, potentially saving the developer significant resources
in time and money (West). Candidate partners could be large pharmaceutical companies and certain nonprofit organizations and foundations. The most important areas to look for when
considering a partnership with a pharmaceutical company are the partnering company’s
commitment to the rare disease community, their ability to find innovative methods for patient
group identification, their ability to navigate patient access to rare disease therapies, and their
intention to give sustained support to the patients and their caregivers (Ascher et al.).
Patient experience data (PED) are collected by diverse stakeholders (including patients, family
members, caregivers, disease research foundations, researchers, and drug manufacturers) and are
intended to provide information about a patient’s experience with a disease, including its impact
and the patient’s preference for or against its treatment (“Public Workshop on Patient-Focused
Drug Development: Developing and Submitting Proposed Draft Guidance Relating to Patient
Experience Data”). Patient-focused drug development (PFDD) meetings are one of the helpful
community engagement mechanisms designed by the FDA. PFDD is a systematic approach to help
ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully
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incorporated into drug development and evaluation. Although pharmaceutical companies are not
involved in such meetings, the makers of orphan drugs can benefit significantly by reviewing the
PED collected in such meetings. The 21st Century Cures Act of 2016 states that the FDA will
conduct public workshops to draft guidance documents related to the PFDD meetings (FDA Plan
for Issuance of Patient-Focused Drug Development Guidance). The most recent workshop was
held on March 19, 2018, and the meeting slides and recordings are available online (Office of the
Commissioner, “Public Workshop on Patient-Focused Drug Development: Developing and
Submitting Proposed Draft Guidance Relating to Patient Experience Data”).

Conclusion
Orphan drugs target rare diseases that affect fewer than 200,000 patients in the U.S. The Orphan
Drug Act was signed in 1983 and provided for various incentives for orphan drug development.
Since then, the orphan drug industry has been growing at a very fast rate. Researchers working on
orphan drugs must learn about these incentives and others that are offered by nonprofit
organizations and groups. Patients and their caregivers are coming together to generate data that
will help drug developers come up with new therapies for rare diseases. Although the drug
approval process remains the same for all drugs, exceptions are made in cases of rare disease drugs.
Not only do orphan drug trials require smaller number of patient populations and condensed phase
studies but they also are eligible for tax credits and grants. Additionally, the U.S. free pricing of
drugs and patients’ higher willingness to pay for rare disease therapies make orphan drug development less expensive and allow for recovering the R&D costs during the seven years of marketing
exclusivity. Pharmaceutical companies increasingly want to invest in these therapies and look for
ways to partner with researchers and small biotech startups.

Practical Guides/Worksheets
FDA Orphan Drug Designation Checklist: For Sponsor Seeking Orphan
Designation
(“CFR—Code of Federal Regulations Title 21”)
This checklist is to make sure that the sponsor has submitted all the required information to the
FDA for obtaining the orphan drug designation for their proposed drug.
1. Have you included the description of the rare disease/condition for which the drug is being or
will be investigated, the proposed use of the drug, and the reasons why such therapy is needed?
Yes
No
2. Have you discussed in the request, the scientific rationale to establish a medically plausible
basis for the use of the drug for the rare disease?
Yes
No
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3. Have you included all copies of pertinent unpublished and published papers that provide
evidence of the medical plausibility of the treatment?
Yes
N/A
4. Is the number of people affected with the disease or condition for which the drug is being
developed is fewer than 200,000 persons in the U.S.?
Yes
No
OR
Is there no reasonable expectation that the sales of the drug will be sufficient to offset the costs
of developing the drug for the U.S. market and the costs of making the drug available in the
United States?
Yes
No
5. Is the estimated prevalence of the disease together with a list of sources (including dates of
information provided and literature citations) included in the documentation?
Yes
No
6. If the drug is a vaccine or a drug intended for diagnosis or prevention of a rare
disease/condition, is the estimated number of people to whom the drug will be administered
annually listed?
Yes
N/A
7. If your drug is the same drug as an already approved drug and seeks orphan drug designation
for the same rare disease, have you justified that the proposed variation may be clinically
superior to the first drug?
Yes
N/A

Resources
1. Orphan Disease Center
a. The Orphan Disease Center (ODC) at Penn, led by Dr. Jim Wilson, provides a unique
set of programs that add value to every drug development stage, from building the
initial knowledge base to enabling therapeutic development. Through their grants, the
Programs of Excellence, international patient registries, Jump Start programs, and a
number of new initiatives, the ODC seeks to drive therapeutic development for rare
diseases. The ODC offers 50+ grant opportunities in 30+ diseases annually to
researchers. Key functions of the ODC include—but are not limited to—uniting
investigators and clinicians within Penn, CHOP, and internationally who are
committed to treating and curing orphan conditions, creating resources for the rare
disease community, and providing means for pharmaceutical and biotech companies
to partner with researchers. The ODC’s Million Dollar Bike Ride pilot grant program
opened in the summer of 2018.
b. http://www.orphandiseasecenter.med.upenn.edu/.
2. Orphan Products Natural History Grants Program

https://repository.upenn.edu/ace/vol1/iss3/13

14

ORPHAN DRUGS

a. The Orphan Products Natural History Grants Program by the OOPD supports studies
that advance rare disease medical product development. The searchable database for
these grants will be available soon.
b. https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Orp
hanProductsNaturalHistoryGrantsProgram/default.htm.
3. Genetic and Rare Diseases Information Center (GARD)
a. The detailed guides for researchers on “Finding Research Participants” and “Where to
find statistics for Rare Diseases” will be available soon on the NIH’s GARD
webpage.
b. https://rarediseases.info.nih.gov/about-gard/pages/23/about-gard.
4. Search database of Orphan Drug designations and approvals
a. If a product receives orphan drug designation, certain information about the orphan
designated product (sponsor’s name, address, and contact information, as well as the
name of the drug, orphan designated use, and the date of designation) is updated
monthly on the searchable database on the FDA’s website.
b. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/.
5. FDA Track Updates
a. Sponsors could subscribe to the FDA track updates to keep track of drugs being
accepted for the expedited programs.
b. https://www.fda.gov/AboutFDA/Transparency/track/default.htm.
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